BioSpace News Archive

Pluri Inc., a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, unveiled a breakthrough in cell manufacturing that potentially solves one of the biggest hurdles facing cell-based industries: cost-effective, industrial scale cell manufacturing.

Compugen Ltd. today announced that it will present new clinical data on COM701 in triple combination with BMS-986207 (anti-TIGIT) and nivolumab in metastatic endometrial cancer at the American Society of Clinical Oncology (ASCO) annual meeting on June 2-6, 2023, in Chicago, Illinois.

Biomica Ltd. today announced that it has closed a financing round of $20 million.

Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023.

Antiva Biosciences today announced the closing of a $53 million Series E equity financing.

Schrödinger, Inc. today published its inaugural Corporate Sustainability Report.

Avacta Group plc announces that the first patient has been dosed in the US under its Investigational New Drug (IND) Application in Avacta’s phase 1 multi-centre trial evaluating the safety and tolerability of AVA6000, a novel tumour targeted form of doxorubicin and Avacta’s first therapeutic product based on its proprietary pre|CISION™ technology.

IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS).

Alphyn Biologics will present for the first time new pediatric data from its Phase 2a clinical trial of a topical candidate for mild-to-moderate atopic dermatitis (AD) at the 22nd European Society for Pediatric Dermatology Congress.